FILTER
LATEST INTERVIEWS
Keith Spence
PRESIDENT & CEO, GLOBAL MINING CAPITAL CORP.
Global Mining Capital Corp. speaks about the prospects of gold and of China’s role as a foreign investor.
Anthony (Tony) Makuch
PRESIDENT AND CEO, KIRKLAND LAKE GOLD
Kirkland Lake Gold explains how it gets the best out of its assets.
Daniel Mitchell
PRESIDENT, ACOPLÁSTICOS
Acoplásticos explains how Colombia’s chemical industry has coped with the COVID-19 pandemic.
Manni Kantipudi & Dr. Ramesh Subramanian
CHIEF EXECUTIVE OFFICER & CHIEF COMMERCIAL OFFICER, GVK BIO
GVK BIO is a global contract research and development organization (CRDO) providing drug discovery and development services to the biopharma industry.
Jago Penrose
CMO, GREEN RESOLUTION
Green Resolution explains its sustainability-incentivized bioremediation technology that it is introducing to treat Canada’s mine tailings.
Ahmet Musul
CHAIRMAN, EKOL LOGISTICS
Ekol provides international freight, warehousing, distribution, foreign trade, customs, and supply-chain management services across Europe.
Ed Ikeguchi
CEO, AICURE
AiCure is an AI and advanced data analytics company targeting the health industry.
Rodrigo Gutierrez
CEO, GTM HOLDINGS
GTM Holdings explains its outlook for the Latin American industrial and specialty chemicals market for the next year.
Martin Cini
DIRECTOR, COPSA COMBUSTIBLES, QUÍMICOS Y ESPECIALIDADES
Copsa is an Argentinian petrochemical company currently expanding its products and services.
Amedeo Anniciello
CEO, STANDARD BANK DRC
Standard Bank DRC builds on its international and African network in an effort to become the preeminent corporate investment bank in DRC.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
